Synmosa Biopharma Corporation (TPEX:4114)

Synmosa Biopharma Revenue

Synmosa Biopharma had revenue of 1.92B TWD in the quarter ending June 30, 2026, with 19.20% growth. This brings the company's total for the last twelve months to 6.68B, up 11.40% year-over-year. In the year 2025, Synmosa Biopharma had annual revenue of 6.19B with 11.53% growth. That makes Synmosa Biopharma the 17,343rd largest company in the world by revenue and 617th in Taiwan.

• Revenue (ttm): 6.68B
• Revenue Growth: +11.40%
• P/S Ratio: 2.20
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 14.72B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• New Drugs Segment 6.00B 92.8%
• Pharmaceutical Ingredients Department 467.25M 7.2%

By Geography

Chart

• Taiwan 5.24B 84.6%
• China 698.28M 11.3%
• Singapore 80.00M 1.3%
• Other 61.76M 1.0%
• Thailand 45.81M 0.7%
• Malaysia 28.43M 0.5%
• United States 25.60M 0.4%
• Canada 11.15M 0.2%

Fiscal year ended Dec 31, 2025 See the full Synmosa Biopharma breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	6.19B	639.71M	11.53%
Dec 31, 2024	5.55B	409.05M	7.96%
Dec 31, 2023	5.14B	754.13M	17.19%
Dec 31, 2022	4.39B	1.15B	35.59%
Dec 31, 2021	3.23B	196.67M	6.47%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error